Beactica scientists describe strategies for fragment-based drug discovery in two publications in Journal of Medicinal Chemistry

04 February 2011

Uppsala, Sweden, February 4, 2011

Beactica, the leading Swedish fragment-based drug discovery company, today announced the publication of two key papers based on in-house research in the field-leading Journal of Medicinal Chemistry*. The papers present methodological advances in SPR biosensor-based drug discovery targeting structurally dynamic proteins, a significant challenge for the pharmaceutical industry, that have been implemented in Beactica’s discovery platform.

The first paper describes the identification of novel chemical scaffolds for inhibition of wild-type and drug-resistant HIV-1 reverse transcriptase by SPR-based fragment screening. The study demonstrates that an efficient experimental design can enable the identification of molecular fragments with desired characteristics and a defined mode of action – also for challenging targets. The second paper outlines concepts for an improved understanding of the druggability of target proteins during fragment-based lead generation. The proprietary methodology developed on the basis of the findings enables an improved evaluation and prioritization of screening hits.

The research is a result of an international collaboration between Beactica, IOTA Pharmaceuticals Ltd, Cambridge, UK, and scientists at Uppsala University, Sweden.

For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560880.

* Publication references

More News

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates

This website uses cookies to improve your user experience. By continuing to browse this site, you agree to our use of cookies. More information. Ok!